Results 31 to 40 of about 11,583 (90)
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins +3 more
wiley +1 more source
Lung cancer (LC) remains the leading cause of global cancer‐related death. Phytochemicals from medicinal plants are increasingly being considered as potential LC treatment agents due to their multi‐targeted action, safety, and accessibility. These have anticancer properties by regulating key molecular signaling pathways.
Md. Rezaul Islam +14 more
wiley +1 more source
Research advances in the applications of mitochondria‐targeted cyanine dyes in imaging
Near‐infrared (NIR) fluorescence imaging, a novel non‐invasive diagnostic tool, plays a crucial role in the imaging and monitoring of solid tumors. At its core are NIR fluorescent dyes, which are widely utilized due to their ability to minimize tissue autofluorescence interference, thereby significantly enhancing the signal‐to‐noise ratio (SNR) and ...
Hongye Liao +8 more
wiley +1 more source
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan +9 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
In Huh7 cells, HIF‐1α is essential as it maintains the expression of proteins involved in glycolysis and steroid/cholesterol biosynthesis both under normoxia and hypoxia. On the other hand, in HeLa cells, these pathways are induced by HIF‐1α only under hypoxia.
Ioanna‐Maria Gkotinakou +6 more
wiley +1 more source
Heterocyclic‐Fused Squaramides: Anionophores With Antimicrobial Activity
Supramolecular medicinal chemistry has allowed for the development of novel drugs for the treatment of cystic fibrosis, and in the fight against cancer. However, little has been done to develop these as antimicrobial agents. Here, we describe the development of novel chemical tools to further develop supramolecular methods to combat the global plight ...
Luke Edward Brennan +3 more
wiley +1 more source
Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)
DM1 is an RNA gain‐of‐function disease caused by CTG repeat expansion, producing toxic r(CUG)exp RNA that sequesters MBNL1 and impairs splicing. This review covers the field of CUG and CTG ligands identified or rationally designed as DM1 drug candidates, highlighting their molecular design, RNA‐ or DNA‐binding modes, in vitro affinities and ...
Camille Richagneux, Anton Granzhan
wiley +1 more source
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su +18 more
wiley +1 more source
What's New? Small cell lung cancer (SCLC) is aggressive and difficult to treat but exhibits high levels of stathmin 1 (STMN1), a candidate therapeutic target. In this study, the authors synthesized a chlorambucil (Chb)‐conjugated pyrrole–imidazole polyamide (PIP) compound targeting the STMN1 promoter and DNA sequences and evaluated its efficacy in ...
Ryohei Yoshikawa +23 more
wiley +1 more source

